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ABSTRACT 
T cell exclusion from the tumour microenvironment (TME) is a major barrier to 
overcoming immune escape.  Here we identify a myeloid-intrinsic mechanism 
governed by the NF-ț%HIIHFWRUPROHFXOH*$''ȕWKDWrestricts tumour-associated 
inflammation and T cell trafficking into tumours.  In various models of solid cancers 
refractory to immunotherapies, including hepatocellular carcinoma (HCC) and 
ovarian adenocarcinoma, Gadd45b inhibition in myeloid cells restored activation of 
pro-inflammatory tumour-associated macrophages (TAM) and intratumoural immune 
infiltration, thereby diminishing oncogenesis.  Our results provide a basis to interpret 
clinical evidence that elevated expression of GADD45B confers poor clinical 
outcomes in most human cancers.  Further, they suggest a therapeutic target in 
*$''ȕIRUUH-programming TAM to overcome immunosuppression and T cell 
exclusion from the TME. 
 
PRECIS 
Findings define a myeloid-based immune checkpoint that restricts T cell trafficking 
into tumours, with potentially important therapeutic implications to generally improve 
the efficacy of cancer immunotherapy. 
 
INTRODUCTION 
Virtually all tumours contain an inflammatory infiltrate of innate and adaptive immune 
cells (1).  Despite their inherent capacity to counter neoplastic progression and 
eliminate nascent tumours, these cells ± especially those of the innate immune 
system ± often have the effect of promoting oncogenesis (1,2).  Accordingly, tumour-
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associated inflammation is now considered a hallmark of cancer (1).  The ability of 
the immune system to influence oncogenesis is currently being exploited to treat 
cancer patients, with the development of many successful anticancer 
immunotherapies (3).  Indeed, therapies blocking pivotal immunoinhibitory 
mechanisms, comprising immune checkpoint molecules, e.g., cytotoxic T lymphocyte 
antigen-4 (CTLA-4) or programmed cell death protein 1 (PD-1), are revolutionising 
the clinical management of certain malignancies, such as metastatic melanoma (4).  
However, major challenges remain, as the majority of patients rarely exhibit an 
objective response to these treatments, due to the absence of a pre-existing 
intratumoural T-cell infiltrate or, in patients with T-cell-infiltrated tumours, the 
dominant inhibitory effects of additional tumour microenvironment (TME)-associated 
molecules (3,5).  Yet, the mechanisms underlying the immunoinhibitory activities of 
the TME are presently poorly understood. 
Tumour-associated macrophages (TAMs) are implicated in various TME-
mediated mechanisms that enable cancers to evade immune attack (3,6,7).  TAMs 
are the main leukocyte population found in most human tumours, where they play a 
key role in restricting local T-cell trafficking and T-cell effector functions (3,6,7).  
Indeed, a high density of TAMs, especially those exhibiting an antiinflammatory and 
immunosuppressive phenotype, correlates with poor clinical outcome in most human 
cancers (7,8).  Accordingly, therapeutic approaches limiting myeloid cell recruitment 
into tumours have resulted in increased TME-based CD8+ effector T-cell infiltration 
and diminished tumour burden in mouse models and early-phase clinical trials (3,6,9-
13).  However, the general macrophage depletion associated with these approaches 
raises important safety concerns.  Therefore, a preferable approach would be to 
reprogramme TAMs toward a proinflammatory phenotype capable of redirecting T-
cell trafficking into tumours and unleashing local antitumour immune responses 
(6,14). 
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Macrophages can differentiate into a spectrum of phenotypic states in 
response to diverse environmental signals.  At sites of infection, ³FODVVLFDOO\´
activated or proinflammatory macrophages (hereafter also occasionally referred to as 
M1-like marophages) arise in response to interferon-Ȗ,)1-ȖDQG7ROO-like receptor 
(TLR) ligands to eliminate invading pathogens, promote inflammation and engage 
the adaptive immune system.  By contrast, ³alternatively´ activated or 
antiinflammatory macrophages (hereafter also occasionally referred to as M2-like 
marophages) DUH³HGXFDWHG´E\LQWHUOHXNLQ-4 (IL-4) and IL-13 at sites of injury to 
terminate inflammation and enable wound healing (7,8).  Interestingly, 
antiinflammatory macrophages resemble the TAMs found in most human cancers, 
where they support tumour progression, metastatic dissemination and cancer 
immune evasion (7,8).  However, little is known about the mechanisms governing the 
opposing functions of macrophages in response to tissue injury, malignancy or 
infection.  Consequently, there are presently no therapeutic agents capable of 
effectively reprogramming TAMs to oppose oncogenesis. 
Recent studies have identified NF-țB transcription factors as key 
determinants in the balance between proinflammatory and antiinflammatory 
macrophage activation in response to infection or tumour-derived signals (15,16).  In 
fact, in addition to orchestrating protective immune and inflammatory responses, the 
NF-țB pathway drives oncogenesis in multiple cancer types by suppressing 
apoptosis of tumour cells and, concurrently, governing TME-based inflammation, 
thereby serving as a central hub linking cancer and inflammation (16,17).  In ovarian 
adenocarcinoma models, macrophage-specific inhibition of the NF-țB-activating 
kinase, Iț%ĮNLQDVH,..ȕ was shown to reverse the antiinflammatory TAM 
phenotype and enhance proinflammatory macrophage activation, thereby causing 
tumour regression (18).  A similar conversion from an antiinflammatory TAM 
activation state supportive of oncogenesis to a proinflammatory activation state that 
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antagonises tumour growth, was reported in melanoma and fibrosarcoma models, in 
mice bearing TAMs lacking NF-țB1/p105 (19).  Notably, this ,..ȕ/NF-țB function in 
suppressing proinflammatory activation was shown to extend beyond the cancer 
context, reflecting the tissue-specific role that I..ȕ1)-țB plays in myeloid cells, 
where opposite to its conventional proinflammatory role, NF-țB drives the resolution 
of inflammation to enable wound healing and prevent tissue damage (20,21). 
Therefore, the IKKȕ1)-țB pathway provides an attractive route to 
therapeutically reverse TME-mediated immunosuppression by reprogramming TAMs 
toward a proinflammatory phenotype (15,18).  However, therapeutically targeting this 
pathway with conventional IKKȕNF-țB inhibitors has not proven possible, due to the 
severe on-target toxicities associated with globally suppressing NF-țB (17).  A logical 
alternative to pharmacologically inhibiting IKKȕNF-țB would be therefore to target 
the non-redundant downstream effectors of the NF-țB antiinflammatory function in 
myelo-monocytic cells.  However, these effectors and their modes of action remain 
poorly understood. 
Here, we report that the NF-țB-regulated protein, GADD45ȕ (22,23), 
mediates an essential myeloid-intrinsic mechanism governing proinflammatory 
macrophage activation and the immunosuppressive activity of the TME that restrict 
CD8+ T-cell trafficking into tumours.  Using three distinct models of solid cancers that 
are largely refractory to immunotherapies, including hepatocellular carcinoma (HCC) 
and ovarian adenocarcinoma, we showed that Gadd45b deletion in myeloid cells 
restores proinflammatory TAM activation and intratumoural CD8+ T-lymphocyte 
infiltration, resulting in diminished tumour growth.  Since we previously showed that 
GADD45ȕadditionally mediates the NF-țB antiapoptotic activity in cancer cells (24), 
our current findings identify GADD45ȕDVDSLYRWDOGRZQVWUHDP hub integrating the 
NF-țB oncogenic functions linking cancer and inflammation.  Our finding that 
elevated GADD45B expression correlates with poor clinical outcomes across most 
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human cancers consolidates the general clinical significance of the GADD45ȕ-
mediated oncogenic mechanism in malignant disease.  Together, these results 
reveal a pathogenically critical, LQQDWHLPPXQLW\³checkpoint´ governed by GADD45ȕ 
that is amenable to therapeutic intervention WR³UH-HGXFDWH´ TAMs and ultimately 
overcome TME-dependent immunosuppression, with profound implications for 
anticancer therapy. 
 
MATERIALS AND METHODS 
 
Human Cancer Datasets 
The human datasets of lung cancer (LUNG), stomach adenocarcinoma (STAD), non-
alcoholic liver hepatocellular carcinoma (LIHC), esophageal carcinoma (ESCA), 
cervical carcinoma (CESC), untreated primary glioblastoma multiforme (GBM), 
cholangiocarcinoma (CHOL), head and neck squamous cell carcinoma (HNSC) and 
kidney clear cell carcinoma (KIRC) were part of The Cancer Genome Atlas (TCGA) 
(25) programme and downloaded from the UCSC Cancer Genomic Browser (26).  
Gene expression profiling was performed on fresh or frozen tissue biopsies using the 
Illumina HiSeq 2000 RNA Sequencing platform.  The estimates of GADD45B 
expression levels were derived from the normalised values in the UCSC Cancer 
Genomic Browser.  The datasets of colon adenocarcinoma (COAD; GSE39582), 
bladder carcinoma (BLCA; GSE13507) and ovarian cancer (OV; GSE9891) were 
deposited in the National Center for Biotechnology Information (NCBI) Gene 
Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo).  The COAD 
dataset was from the French national Cartes d'Identité des Tumeurs (CIT) 
programme and generated using the Affymetrix Human Genome U133 Plus 2.0 
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Array platform (27).  The BLCA dataset was from the Chungbuk National University 
Hospital and generated using the Illumina human-6 v2.0 expression beadchip 
platform (28).  The OV dataset was from the Australian Ovarian Cancer Study, Royal 
Brisbane Hospital, Westmead Hospital, and Netherlands Cancer Institute and 
generated using the Affymetrix Human Genome U133 Plus 2.0 Array platform (29).  
The relative GADD45B mRNA expression levels in these datasets were derived from 
the normalised values present in the GEO database.  The breast carcinoma dataset 
(BRCA) was from the tumour banks in the UK and Canada, and gene profiling data 
were generated using the Illumina HumanHT-12 V3 platform and deposited on 
Oncomine® Research Premium Edition (30).  
The gene profiling data from each dataset were downloaded together with the 
accompanying clinical information.  Where possible, the series were obtained from 
patients at an early disease stage and datasets with a sufficient number of patients 
with Recurrence Free Survival (RFS) information.  In the other cases, where this was 
not possible, the series consisted of Overall Survival (OS) data and/or the entire 
patient dataset.  Patients were stratified into two groups on the basis of the 
GADD45B mRNA expression levels.  In each case, quintiles, quartiles, tertiles and 
95th percentiles were used as thresholds, and the best fits are reported in Figure 1A-
1M. 
 
Cell Culture and Macrophage Isolation and Treatment  
The C57BL/6 mouse fibrosarcoma cell line, MCA-203 was kindly provided by I. 
Marigo and V. Bronte and cultured in high-JOXFRVH'XOEHFFR¶VPRGLILHG(DJOH¶V
medium (DMEM; with L-glutamine, without sodium pyruvate; Gibco) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich), antibiotics (150 
U/mL penicillin, 200 U/mL streptomycin), 1P0+(3(6*LEFRȝ0ȕ-
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mercaptoethanol and 2 mM L-glutamine (Gibco).  The C57BL/6 mouse ovarian 
carcinoma cell line, ID8-Luc, stably expressing firefly luciferase (Luc), was previously 
described (18) and cultured in high-glucose DMEM (with L-glutamine, without sodium 
pyruvate; Gibco) supplemented with 4% heat-inactivated FBS (Sigma-Aldrich), 
antibiotics (150 U/mL penicillin, 200 U/mL streptomycin), ITS+1 Liquid Media 
Supplement ȝJPOLQVXOLQȝJ/ml transferrin, 5 ng/ml sodium selenite; Sigma-
Aldrich) and 2 mM L-glutamine (Gibco).  Cells were cultured in a humidified incubator 
in 5% CO2 at 37°C.  All cell lines were routinely tested using a Mycoplasma Detection 
Kit (ATCC).  Before injection in vivo, cell lines were also routinely screened for other 
infectious agents using the Mouse Essential CLEAR Panel (Charles River).  The cell 
lines authentication for the MCA-203 and ID8-Luc murine cell lines has not been 
possible because these cell lines are not commercially available.  Cells were used for 
the experiments between 5 and 7 days upon thawing. 
BMDMs were prepared from 6 to 10 weeks old Gadd45bíí and Gadd45b+/+ 
C57BL/6J mice as previously described (21). BMDMs were treated with LPS (E. coli 
serotype O55:B5, 100 ng/mL; Sigma-$OGULFKDQGPRXVHUHFRPELQDQW,)1Ȗ
ng/mL; Sigma-Aldrich) or with mouse recombinant IL-4 (20 ng/mL; Peprotech) and 
mouse recombinant IL-13 (20 ng/mL; Peprotech).  The p38 inhibitors used were: 
9[ȝ06HOOHFNFKHP); Skepinone-/ȝ06HOOHFNFKHP6%
ȝ0&HOO6LJQDOOLQJ7HFKQRORJ\ 
For TAM isolation, intraperitoneal cells were harvested from ID8-Luc tumour-
bearing mice by peritoneal lavage with 1x PBS and passed through a 70-ȝPFHOO
strainer (BD Biosciences), following red blood cell removal with RBC lysis buffer 
(Sigma-$OGULFK7$0VZHUHVHSDUDWHGXVLQJ0$&60LFUR%HDG7HFKQRORJ\
(Miltenyi Biotec) by negative selection with anti-Ly-6G MicroBead Kit, mouse, 
followed by positive selection with CD11b MicroBeads, human and mouse (Miltenyi 
%LRWHFDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV 
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Further information on the procedures for BMDM isolation can be found in the 
Supplementary Information. 
BMDM/Tumour Cell Co-Culture  
Gadd45bíí and Gadd45b+/+ BMDMs were prepared as above and co-cultured with 
ID8-Luc or MCA-203 tumour cells, without direct cell-to-cell contact, according to 
established protocols (18,31).  Further information on the procedures for 
BMDM/tumour cell co-culture can be found in the Supplementary Information. 
 
Mice 
C57BL/6Jx129/SvJ Gadd45bíí mice were previously described (32).  Gadd45b+/+ 
littermates were co-housed and used as controls.  C57BL/6J Gadd45bíí and 
Gadd45b+/+ mice were obtained by backcrossing the corresponding 
C57BL/6Jx129/SvJ lines onto C57BL/6J to at least the N14 backcross generation.  
C57BL/6J CD45.1/Ly5.1+ mice (B6.SJL-Ptprca Pepcb/BoyJ) and C57BL/6J LysM-cre 
transgenic mice were purchased from The Jackson Laboratory.  C57BL/6J 
Gadd45bíí and Gadd45b+/+ mice, expressing either CD45.2/Ly5.2+ or 
CD45.1/Ly5.1+, were co-housed and bred as separate colonies. 
Conditional Gadd45b knockout mice, carrying loxP-flanked Gadd45b alleles 
(Gadd45bF), were generated at Taconic Biosciences using conventional gene 
targeting technology in embryonic stem (ES) cells.  Homozygous Gadd45bF/F mice 
were obtained by the inter-breeding of Gadd45bF/+ mice.  Gadd45bǻ0ǻ0 mice, 
specifically lacking Gadd45b in the myeloid lineage, were generated by crossing 
Gadd45bF/F mice with C57BL/6J LysM-cre mice (The Jackson Laboratory), 
expressing a Cre recombinase transgene under the control of the myeloid-specific 
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LysM promoter (33).  Co-housed Gadd45bF/F littermates were used as controls for 
the experiments. 
Mice were housed in ventilated cages in a pathogen-free mouse facility of the 
Central Biomedical Services at Imperial College London and used in accordance with 
established institutional guidelines, under the authority of UK Home Office project 
license, P75F16A53 (see: Guidelines on the Operation of Animals [Scientific 
Procedures] Act of 1986).  Separate mouse colonies were maintained in filtered top 
cages on autoclaved food, water and bedding in the Conventional Mouse Facility at 
WKH8QLYHUVLW\RI/¶$TXLOD, and experimental procedures were performed in 
accordance with national and international laws and regulations (see: European 
Economic Community Council Directive 86/609, OJ L 358, 1, December 12, 1987; 
Italian Legislative Decree 116/92, Gazzetta Ufficiale della Republica Italiana no.40, 
February 18, 1992; National Institutes of Health Publication no.85-23, 1985), under 
WKHDSSURYDORIWKH8QLYHUVLW\RI/¶$TXLOD,QWHUQDO&RPPLWWHHDQGWKH,WDOLDQ0LQLVWU\
of Health. 
Further information on the procedures used for the generation of Gadd45bF/F 
mice can be found in the Supplementary Information. 
 
BM Chimaeras  
Congenic CD45.1/Ly5.1+ Gadd45bíí and Gadd45b+/+ mice were generated by 
crossing the corresponding C57BL/6J lines (CD45.2/Ly5.2+) with C57BL/6J B6.SJL-
Ptprca Pepcb/BoyJ mice (The Jackson Laboratory), carrying homozygous Ptprca 
(CD45.1/Ly5.1) alleles, and used as donors in BM adoptive transfer experiments to 
distinguish between haematopoietic-derived cells of recipient (CD45.2/Ly5.2+) and 
donor (CD45.1/Ly5.1+) origin.  For these experiments, BM cells were harvested from 
femurs and tibiae of 6 to 10 weeks old CD45.1/Ly5.1+ Gadd45bíí or Gadd45b+/+ 
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males under aseptic conditions.  Red blood cells were lysed using RBC lysis buffer 
(Sigma-Aldrich), washed in serum-free medium, counted and re-suspended in 1x 
PBS.  4 (Protocol A) or 16 (Protocol B) weeks old C57BL/6J Gadd45bíí and 
Gadd45b+/+ male recipients, carrying Ptprcb (CD45.2/Ly5.2) alleles, were lethally 
irradiated with a single dose of 9.5 Gy and, 24 hours later, intravenously injected via 
the tail vein with 5 x 106 BM donor cells, in order to generate all four possible 
chimaerism combinations.  BM reconstitution with CD45.1/Ly5.1+ donor cells was 
verified after adoptive transfer by FACS analysis of blood leukocytes. 
 
DEN Treatment and HCC Induction  
For the initiation-only model of HCC, 15 to 17 days old Gadd45b-/- and Gadd45b+/+ 
males on a C57Bl/6Jx129/SvJ or C57Bl/6J background, as indicated, were injected 
intraperitoneally with a single dose of DEN (5 mg/kg and 20 mg/kg, respectively; 
Sigma-Aldrich).  At the indicated endpoints, mice were sacrificed and their livers 
removed, photographed and separated into individual lobes.  Externally visible 
WXPRXUVPPZHUHPHDVXUHGXVLQJDFDOLSHUDQd counted.  Tumour areas were 
FDOFXODWHGXVLQJWKHIRUPXODʌGLDPHWHUGLDPHWHU2/4 (34).  For histological 
evaluations, liver tissue was fixed in 10% neutral buffered formalin solution and 
paraffin embedded.  The remaining liver tissue was microdissected into tumour and 
non-tumour tissue and stored at -80°C for molecular evaluation. 
For HCC induction in the tumour initiation-promotion model, mice were 
treated according to two distinct experimental setups, designated as Protocol A and 
Protocol B.  As part of Protocol A, 4 weeks old C57BL/6J males (CD45.2/Ly5.2+) 
were adoptively transferred with BM from CD45.1/Ly5.1+ males, and, 4 weeks later, 
intravenously treated twice with RIȝ/RIFORGURQDWHOLSRVRPHVWRGHSOHWH
endogenous Kupffer cells.  Clodronate liposomes, containing approximately 5 mg/mL 
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of clodronate, were prepared as previously described and were provided by N. Van 
Rooijen (ClodronateLiposomes.org) (35). 10 weeks after clodronate liposome 
administration, BM chimaeras were intraperitoneally injected with a single dose of 
DEN (100 mg/kg; Sigma-Aldrich) and, 4 weeks later, placed on treatment with 0.07% 
of the tumour promoter, phenobarbital (Sigma-Aldrich), in the drinking water until the 
experimental endpoint, according to an established tumour initiation-promotion 
protocol (33).  As part of Protocol B, 4 weeks old C57BL/6J males (CD45.2/Ly5.2+) 
were intraperitoneally injected with 75 mg/kg of DEN (Sigma-Aldrich) and, 4 weeks 
later, placed on treatment with 0.07% phenobarbital (Sigma-Aldrich) in the drinking 
water, as above, in order to induce HCC initiation and early promotion.  After 8 
weeks, mice were adoptively transferred with BM from congenic CD45.1/Ly5.1+ 
males and, 4 weeks later, treateGZLWKȝ/RIFORGURQDWHOLSRVRPHVDVDERYHWR
deplete Kupffer cells.  At the indicated endpoints, mice were sacrificed, and their 
livers removed, photographed and separated into individual lobes.  Externally visible 
WXPRXUVPPZHUHFRXQWHG)RUKLVWRORJLFDOHYDOXDWLRQVOLYHUtissue was fixed 
and paraffin-embedded or embedded in Tissue-Tek OCT compound (Sakura 
Finetek) for frozen block preparation.  BM-cell reconstitution and liver repopulation 
with donor-derived CD45.1/Ly5.1+ Kupffer cells were confirmed in each group of BM 
chimaeras by FACS analysis of spleen and BM cells and immunofluorescence 
staining of frozen liver sections, respectively. 
To validate the procedure for Kupffer cell depletion, a separate group of 
C57BL/6J mice was intravenously injected ZLWKDVLQJOHGRVHRIȝ/RIFORGURQDWH
or PBS liposomes.  At the indicated time points, mice were sacrificed, and their livers 
and spleens were removed, fixed and paraffin-embedded for immunohistological 
evaluation of macrophage depletion. 
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Tumour Allografts  
For fibrosarcoma allografts, 6 to 8 weeks old C57BL/6J Gadd45bíí and Gadd45b+/+ 
males were subcutaneously injected in the right flank with 1.0 x 105 MCA-203 cells in 
ȝ/RIVWHULOH[3%6XVLQJD-mL Leur-/RN7LSV\ULQJH%'%LRVFLHQFHVZLWK
a 25-guage needle.  MCA-203 cells were harvested from exponentially growing 
cultures, washed once with serum-free medium and re-suspended in 1x PBS 
immediately before injection.  Once tumours became palpable, tumour growth was 
monitored every other day using a vernier caliper.  Tumour volumes were calculated 
using the formula: volume = AxB2/2 (where A is the larger diameter, and B is the 
smaller diameter of the tumour) (24).  19 days after tumour cell injection, mice were 
sacrificed, and tumours were removed and embedded in Tissue-Tek OCT compound 
(Sakura Finetek) for frozen block preparation.  To investigate the macrophage-
VSHFLILFUROHRI*DGGȕLQVDUFRPDJHQHVLVWRZHHNVROGGadd45bF/F and 
Gadd45bǻǻ males were injected with 1.0 x 105 exponentially growing MCA-203 cells 
LQȝ/RIVWHULOH[3%6FRQWDLQLQJ0DWULJHO&RUQLQJ  Tumour growth was 
monitored using a vernier caliper, and tumor volumes were calculated as above.  At 
the indicated endpoint, mice were sacrificed, and tumours photographed.  
For the in vivo depletion of CD8+ T cells, 8 to 12 weeks old C57BL/6J 
Gadd45bíí and Gadd45b+/+ females mice were treated intraperitoneally with 250 ȝJ
of anti-CD8b antibody (Lyt 3.2; clone 53-5.8; BioXCell) or rat IgG isotype-matched 
control antibody (clone HRPN; BioXCell) at day -1 and day 0 before the injection of 
1.0 x 105 exponentially growing MCA-203 cells prepared as described above, and 
then twice a week with the same dose of antibody until the experimental endpoint. 
Tumour growth was monitored as described above.  The efficiency of the antibody-
mediated CD8+ T-cell depletion was determined by FACS analysis of spleen cells 
using anti-CD8b-APC (130-106-315), anti-CD4-APC (130-109-415) and anti-CD3-
FITC (130-108-836) antibodies (Miltenyi Biotec). 
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For ovarian carcinoma allografts, 11 to 12 weeks old C57BL/6J Gadd45bíí 
and Gadd45b+/+ females were intraperitoneally injected with exponentially growing 
1.0 x 106 ID8-/XFFHOOVLQȝ/RIVWHULOHVDOLQHVROXWLRQXVLQJD-mL Leur-/RN
Tip syringe (BD Biosciences) with a 25-guage needle. Tumour growth was monitored 
weekly starting 6 weeks after tumour cell injection by bioluminescence imaging.   
The analyses of the macrophage-specific UROHRI*DGGȕLQRYDULDQ
oncogenesis were performed essentially as previously described (18).  Briefly, 8 
weeks old C57BL/6J Gadd45b+/+ females (Harlan Laboratories) were intraperitoneally 
injected with 2 x 106 exponentially growing ID8-/XFFHOOVLQȝ/RIVWHULOHVDOLQH
solution, and tumours were allowed to grow, as above.  After 5 weeks, mice were 
randomised into two groups and intraperitoneally injected with 10 x 106 BMDMs from 
C57BL/6J Gadd45bíí or Gadd45b+/+ PLFHLQȝ/RIVWHULOHVDOLQHVROXWLRQ,'-
Luc tumour growth was monitored weekly by bioluminescence imaging.  Further 
information on the procedures used for bioimaging can be found in the 
Supplementary Information. 
 
Histopathological Analyses, Immunohistochemistry, Immunofluorescence and 
TUNEL Assays  
Detailed information on the procedures used for histopathological analyses, 
immunohistochemistry, immunofluorescence and TUNEL assays can be found in the 
Supplementary Information. 
 
Quantitative Real-Time Polymerase-Chain Reaction (qRT-PCR) Analysis, 
Western Blots and FACS Analysis 
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Detailed information on the procedures used for RNA extraction, qRT-PCR reactions, 
western blotting and FACS analysis can be found in the Supplementary Information. 
 
Statistical Analysis  
Data were analyzed using Graph Pad Prism version 7.0 (GraphPad Software) or R 
(www.R-project.org).  Statistical analyses of the results were performed using either 
two-tailed t test or two-tailed Mann-Whitney U test, depending on the distribution of 
the data.  Assumptions concerning the data (for example, normal distribution and 
similar variation between experimental groups) were examined for appropriateness 
before statistical tests were conducted.  p values < 0.05 were considered statistically 
significant.  For ovarian carcinoma allografts, outliers were detected and removed 
according to the default options of the software used. 
Survival analyses were performed in R, using package survival.  Differences 
between the survival distributions within each dataset were assessed for statistical 
significance using Kaplan-Meier curves and the log-rank test, with p values < 0.05 
taken as the level of significance. 
For the sample size of the animals used in this study, it was fixed in a 
prospective manner; no statistical method was used to predetermine sample size.  
Mice with the indicated genotypes were included in the study without any 
randomization.  Histological analyses were performed in a single-blinded fashion.  No 
blinding was used for the remaining analyses. 
 
RESULTS 
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GADD45B Expression Denotes Aggressive Malignant Disease Across 
Most Human Cancers 
We recently identified the product of the NF-țB-regulated gene, GADD45B, as an 
essential survival factor and novel therapeutic target in multiple myeloma (24).  We 
therefore investigated whether GADD45B was involved in any types of malignancy 
beyond multiple myeloma.  Strikingly, in publicly available patient datasets, elevated 
GADD45B expression correlated with rapid disease progression in thirteen out of the 
top fifteen solid cancers for mortality worldwide (36).  When patients with prevalent 
disease subtypes were stratified at diagnosis on the basis of GADD45B expression 
in the tumour tissues, the patient cohorts expressing high GADD45B levels exhibited 
significantly shorter recurrence-free survival (RFS) and/or overall survival (OS) than 
the corresponding cohorts expressing low GADD45B mRNA levels (Figures 1A-1M).  
Collectively, these results identify GADD45ȕ as a hallmark of aggressive pathology 
across the most prevalent human cancer types and postulate its general clinical 
significance in malignant disease. 
 
Gadd45b Loss Reduces Chemically Induced Hepatocellular 
Carcinogenesis 
The role of IKKȕ/NF-ț%LQ hepatocellular carcinogenesis is controversial (16,17).  
Indeed, in the widely used diethylnitrosamine (DEN) experimental model of HCC, 
hepatocyte-specific Ikkb ablation was previously shown to promote, rather than 
inhibit, oncogenesis (33).  Therefore, to clarify the basis for the observed correlation 
between expression of the IKKȕ/NF-ț%-regulated effector, GADD45B, and 
aggressive disease pathology in HCC datasets (Figure 1C), we sought to investigate 
whether Gadd45ȕZDVLQYROYHG in this process.  15-day-old Gadd45b-/- and 
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Gadd45b+/+ C57BL/6 males were treated with a single intraperitoneal injection of the 
carcinogen, DEN, according to an established protocol for HCC induction (33).  As 
expected, all Gadd45b+/+ mice given DEN developed typical HCCs within 9 months 
(Figures 2A-2E).  Interestingly, Gadd45b deletion significantly reduced the number of 
HCCs (Figure 2A, Figure 2D).  Tumour surface area and maximum tumour diameter 
were also markedly reduced in Gadd45b-/- mice relative to controls (Figures 2B-2C). 
Histological analysis confirmed the more than three-fold lower number of 
HCCs in Gadd45b-/- than Gadd45b+/+ livers (Figure 2F).  As typically seen in C57BL/6 
mice, DEN-induced tumours predominantly consisted of adenomas, with only few 
sporadic carcinomas, hereafter collectively referred to as HCCs.  Similar results were 
obtained using 129/SvJxC57BL/6 mice (Figures S1A-S1F).  Notably, Gadd45b-/- and 
Gadd45b+/+ HCCs displayed no difference with respect to tumour grade, mitotic index 
or necrosis grade, and similar percentages of proliferating and apoptotic cells 
(Figures S1G-S1J).  Likewise, the analysis of cell-cycle regulators and oncogenic 
factors showed no difference between Gadd45b-/- and Gadd45b+/+ livers when 
comparing corresponding tumour or non-tumour tissues (Figure S1K).  Hence, 
opposite to hepatocyte-specific Ikkb loss (33), Gadd45b ablation inhibits DEN-
induced hepatocellular carcinogenesis, while having no effect on tumour cell 
proliferation or apoptosis. 
 
Gadd45b Loss Augments Tumour-Associated Macrophage and T-Cell 
Infiltration and TLS Formation 
Despite the otherwise similar histological and molecular characteristics (Figure 2E, 
Figure S1E, Figures S1G-S1K), Gadd45b-/- HCCs contained considerably more and 
larger immunoinflammatory infiltrates than Gadd45b+/+ tumours (Figure 2G; see also 
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Figure 2E, Figure 2H, Figure S1E).  Strikingly, in Gadd45b-/-, but not Gadd45b+/+ 
HCCs, intratumoural infiltrates were also often organised into follicle-like aggregates, 
reminiscent of tertiary lymphoid structures (TLSs) (Figures 2G-2J; see also Figure 
2E, Figure S1E, Figure S2A-S2B), denoting sites of thriving adaptive immune 
reactions and favourable clinical outcome in multiple human cancers (37).  
Consistently, whereas only 33% of Gadd45b+/+ mice contained at least one HCC 
featuring TLS-like aggregates (hereafter referred to as TLSs), well-organised TLSs 
were often found in multiple HCCs in 80% of Gadd45b-/- mice (Figure S2C; see also 
Figure S2D). 
In both Gadd45b-/- and Gadd45b+/+ HCCs, intratumoural leukocyte infiltrates 
predominantly consisted of lymphocytes and macrophages, with only few sparse 
granulocytes (Figures 2I-2J).  However, Gadd45b-/- HCCs contained considerably 
more F4/80+ and IBA-1+ macrophages and B and T lymphocytes than Gadd45b+/+ 
HCCs (Figures 2I-2J; see also Figures 3A-3B).  Crucially, Gadd45b loss also 
increased the intratumoural infiltration by CD8+ T cells, a hallmark of effective 
antitumour immune responses (Figures 2I-2J).  Interestingly, whereas the increased 
numbers of IBA-1+ macrophages and lymphocytes observed in Gadd45b-/- HCCs 
were mostly due to the greater frequency and larger size of TLSs, the increased 
intratumoural F4/80+ macrophage numbers were mainly attributable to the higher 
density of these cells outside TLSs.  Plausibly, this distinct effect of Gadd45b loss on 
the F4/80+ macrophage distribution within the TME reflects the central role of these 
cells LQVHQVLQJ³GDQJHU´ signals and antigens arising from tumour cells and 
processing them into cues to elicit reciprocal adaptive immune reactions (38).  
Irrespective of the mechanism(s), our data demonstrate that Gadd45b loss 
profoundly affects tumour-associated inflammation and macrophage and lymphocyte 
infiltration within DEN-induced HCCs. 
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Since resident liver macrophages, so-called Kupffer cells, play a central role 
in DEN-induced carcinogenesis through a mechanism that depends on IKK/NF-țB 
(17,33), ZHIXUWKHULQYHVWLJDWHGWKHHIIHFWRI*DGGȕRQ7$0V,QNHHSLQJ with their 
heightened state of inflammation, Gadd45b-/- HCCs contained a significantly higher 
number of myeloid-like cells expressing inflammatory markers, such as inducible 
nitric-oxide synthase (iNOS) and cyclo-oxygenase-2 (COX-2), than Gadd45b+/+ 
HCCs (14) (Figures 3A-3B, Figure S2E).  They also contained markedly more IBA-1+ 
macrophages within well-organised TLSs expressing major histocompatibility 
complex class II (MHC-II), a key antigen-presenting molecule and prototypical 
proinflammatory activation marker (7) (Figures 3C-3D; see also Figures 3A-3B, 
Figure S2E), thus phenocopying the effects of myeloid-associated IKKȕ/NF-ț%
inhibition on TAMs (18,19).  Underscoring the significance of these findings, 
Gadd45b-/- HCCs additionally displayed considerably more TLS-associated cells 
expressing the immunoinhibitory enzyme, indoleamine-2,3-dioxygenase (IDO) 
(Figures 3E-3F), suggesting that the upregulation of immune checkpoint molecules, 
such as IDO (3,4), could conceal the full immunostimulatory potential of Gadd45b 
loss.  By contrast, Gadd45b deletion had no effect on alternative TAM activation, 
which is more typical of established neoplasias (7,8) (Figures 3A-3B; see also Figure 
S2E).  Hence, Gadd45b loss enhances proinflammatory TAM activation within HCCs.  
Collectively, these findings indicate that *DGGȕSOD\VDQessential role in curbing 
proinflammatory TAM activation, intratumoural lymphocyte infiltration and TLS 
formation within established neoplasias. 
 
Gadd45b Loss Augments DEN-Induced Hepatocyte Toxicity, But Not 
Hepatocyte Proliferation 
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While in established tumours macrophage-driven inflammation has the potential to 
elicit antitumour immune responses, it was shown that when it ensues in response to 
acute DEN-induced liver damage, this inflammation triggers compensatory 
hepatocyte proliferation, thereby facilitating HCC initiation (33).  We therefore 
examined the effect of Gadd45b loss on the acute liver response to DEN 
administration.  As expected, in Gadd45b+/+ mice, DEN injection induced hepatocyte 
apoptosis at 48 hr (Figures S3A-S3B).  The number of apoptotic hepatocytes was 
modestly increased, in Gadd45b-/- mice after DEN administration, but not at baseline, 
compared to controls (Figures S3A-S3B).  Circulating liver enzymes, indicative of 
hepatocyte damage, were also higher in DEN-treated Gadd45b-/- than Gadd45b+/+ 
mice (Figure S3C), even though the livers of these mice displayed similarly low 
numbers of dead cells (Figures S3D-S3E). 
Since DEN-induced hepatocyte toxicity involves JNK activation (33,39), and 
Gadd45ȕKDVWKHFDSDFLW\WRVXSSUHVV-1. signalling in the liver (32), we 
investigated the effects of Gadd45b loss on MAPK activation by DEN.  As shown in 
Figure S3F, DEN induced strong JNK activation in Gadd45b+/+ livers, but this 
activation was unaffected by Gadd45b loss.  Gadd45b deficiency also had no effect 
on DEN-induced ERK, p38 or STAT3 signalling, nor did it have any effect on 
hepatocyte proliferation, either at baseline or following DEN injection (Figures S3G-
S3H).  Hence, Gadd45b loss mildly augments DEN-induced liver damage, but does 
not affect hepatocyte proliferation and is, therefore, unlikely to impact HCC 
development by affecting the acute liver response to DEN. 
 
Haematopoietic Cell-Specific Gadd45b Loss Reduces DEN-Induced 
Carcinogenesis 
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Given the association between diminished HCC burden and increased intratumoural 
immunoinflammatory infiltration observed in Gadd45b-/- mice, we hypothesised that 
Gadd45ȕ promotes hepatocellular carcinogenesis by operating within immune and 
inflammatory cells.  To distinguish between the oncogenic roles of Gadd45ȕ in the 
TME and the hepatic parenchyma, we generated bone marrow (BM) chimaeras 
harbouring all possible combinations of tissue-specific Gadd45b deficiency in the 
parenchymal tissue and BM-derived cells (Figure 4A).  Given the importance of 
Kupffer cells in driving DEN-induced carcinogenesis (17,33), chimaeric mice were 
then treated with clodronate liposomes to deplete endogenous Kupffer cells and 
thereby permit liver repopulation with donor-derived Kupffer cells, following which, 
mice were administered DEN, along with the tumour promoter, phenobarbital 
(Protocol A; Figure 4A), according to an established tumour initiation-promotion 
protocol (33).  
Successful BM-cell reconstitution and host Kupffer-cell liver repopulation with 
donor-derived Kupffer cells were confirmed by FACS and immunofluorescence 
analyses, respectively (Figures S4A-S4B; see also Figure S4C).  As expected, DEN-
treated chimaeras bearing isogenic Gadd45b+/+ or Gadd45b-/- tissues (WTBM:WTHost 
and KOBM:KOHost, respectively) developed similar numbers of HCCs as their non-
transplanted counterparts (Figures 4B-4C; see also Figure 2A, Figure S1A).  Notably, 
however, the ratio between HCC numbers in these mice was more than five folds 
(Figure 4B; compare WTBM:WTHost with KOBM:KOHost) relative to the approximately 
two-fold ratio observed in mice treated according to the tumour initiation-only protocol 
(Figure 2A, Figure S1A), suggesting that Gadd45b loss has a greater impact on HCC 
progression than on tumour initiation (discussed below). 
Strikingly, selective Gadd45b ablation in BM-derived cells reduced the 
numbers of HCCs to similar levels as in isogenic Gadd45b-/- mice (Figure 4B; 
compare KOBM:WTHost with WTBM:WTHost; also compare KOBM:WTHost with 
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KOBM:KOHost).  By contrast, selective Gadd45b deletion in the hepatic parenchyma 
did not significantly affect HCC burden (compare WTBM:KOHost with WTBM:WTHost).  In 
keeping with these findings, the additional Gadd45b ablation in BM-derived cells did 
result in a significant reduction in tumour numbers in Gadd45b-/- hosts (compare 
WTBM:KOHost with KOBM:KOHost).  Hence, selective Gadd45b loss in hematopoietic-
derived cells is sufficient on its own to fully recapitulate the phenotype of Gadd45b-/- 
mice in DEN-induced carcinogenesis.  We concluded that *DGGȕ promotes this 
oncogenic process largely by operating within immune and inflammatory cells. 
 
Gadd45b Loss Hinders HCC Progression 
Given that the effect of Gadd45b loss on DEN-induced carcinogenesis intensifies in a 
tumour initiation-promotion model (Figures 4B-4C), is associated with increased 
TME-based inflammation (Figures 2G-2J, Figures 3A-3F, Figures S2A-S2E), and 
does not affect the acute hepatocyte proliferative response to DEN (Figures S3G-
S3H), we hypothesised that Gadd45ȕ contributes to HCC progression, rather than 
initiation.  As part of so-called ³3URWRFRO%´)LJXUH 4D), mice of both genotypes were 
first challenged with DEN and placed on treatment with phenobarbital, and then 
adoptively transferred with Gadd45b-/- or Gadd45b+/+ BM, followed by Kupffer cell 
depletion, as for Protocol A.  Because, the Gadd45b status of inflammatory cells is 
modified 3 months after DEN injection, when preneoplastic foci have already largely 
progressed to HCCs (40), we reasoned that Protocol B would allow to distinguish 
between roles of Gadd45ȕ in tumour progression versus roles in tumour initiation. 
Successful BM-cell engraftment and Kupffer-cell liver repopulation with 
donor-derived cells were verified as for Protocol A (Figures S4D-S4E).  As expected, 
12 months after DEN injection, the ratio between HCC numbers of isogenic 
Gadd45b+/+ and Gadd45b-/- mice was similar to that observed with Protocol A 
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(Figures 4E-4F; compare KOBM:KOHost with WTBM:WTHost; see also Figures 4B-4C).  
Strikingly, even when introduced after tumour initiation had already largely occurred 
in Gadd45b+/+ livers, BM-derived cell-specific Gadd45b ablation retained a virtually 
intact capacity to diminish oncogenesis (Figure 4E; compare KOBM:WTHost with 
WTBM:WTHost).  Accordingly, concomitant Gadd45b ablation in the hepatic 
parenchyma had no additional effect on HCC burden (compare KOBM:WTHost with 
KOBM:KOHost).  Reciprocally, the introduction of Gadd45b+/+ BM into Gadd45b-/- hosts, 
3 months after DEN injection, was still effective in restoring oncogenesis (compare 
WTBM:KOHost with KOBM:KOHost).  Notably, these results were broadly equivalent to 
those obtained with Protocol A (see Figure 4B).  Collectively, these findings reinforce 
the conclusions that the Gadd45ȕ oncogenic function in DEN-induced 
tumourigenesis is largely restricted to the haematopoietic system and impacts upon 
tumour progression, while likely having little impact upon tumour initiation. 
 
TME-Associated Gadd45b Loss in Fibrosarcoma Augments TAM 
Infiltration and Proinflammatory Activation, While Reducing Tumour 
Growth 
To clarify the basis for the tumour-promoting activity of Gadd45ȕ in the TME and its 
significance in the association between GADD45B expression and aggressive 
disease pathology across human cancer types (Figures 1A-1M), we sought to 
investigate other model systems of established neoplasia, in which IKK/NF-țB drives 
oncogenesis by operating in immunoinflammatory cells.  We reasoned that this 
approach could additionally clarify the basis for the oncogenic function of IKK/NF-țB 
itself in these cells.  Indeed, while IKK/NF-țB inhibition in different epithelial cell types 
was shown to have discordant outcomes on oncogenesis, this inhibition in 
inflammatory cells, especially those of the myeloid lineage, has invariably resulted in 
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oncogenesis suppression (16).  We chose an initiated fibrosarcoma model in which 
haematopoietic cell-specific NF-țB1/p105 ablation was shown to augment TME-
based inflammation and proinflammatory TAM activation, resulting in diminished 
tumour growth (19).  As expected, subcutaneously implanted MCA-203 
fibrosarcomas grew rapidly in immunocompetent C57BL/6 Gadd45b+/+ mice (Figure 
5A).  Notably, however, tumour growth was markedly reduced in Gadd45b-/- hosts, 
thereby confirming in a different model system the essential oncogenic role of 
Gadd45ȕ in the TME. 
As seen with HCC (Figures 2I-2J, Figures 3A-3D), the Gadd45b-/- TME 
contained a higher number of TAMs than the Gadd45b+/+ TME (Figures 5B, Figure 
S5A).  Fibrosarcomas from Gadd45b-/- mice also contained more T cells than 
tumours from Gadd45b+/+ hosts, although at the early time point examined (i.e., d19), 
this T-cell increase had not reached statistical significance (Figures 5B, Figure S5A).  
Plausibly, this reflected the rapid evolution of fibrosarcoma allografts relative to 
endogenous DEN-induced HCCs and the delayed onset of adaptive relative to innate 
immune reactions (see also Figures 2I-2J).  Indeed, the depletion of cytotoxic CD8+ T 
cells by the use of a CD8-specific antibody resulted in a marked increase in 
fibrosarcoma growth, completely ablating any inhibitory effect of Gadd45b loss on 
oncogenesis (Figures 5C-5D, Figure S5B; compare tumour growth in Gadd45b-/- 
mice treated with anti-CD8 versus control antibody; also note the similar tumour 
growth in Gadd45b-/- and Gadd45b+/+ mice treated with the anti-CD8 antibody; see 
also Figure S5C).  These data unequivocally demonstrate the critical importance of 
cytotoxic CD8+ T cells in the antitumor effect of TME-associated Gadd45B loss.  By 
contrast, TME-infiltrating B cells and granulocytes were unaffected by Gadd45b loss. 
Underscoring the significance of the effects of Gadd45ȕ on TAMs, these cells 
comprised the major cellular component of the immunoinflammatory infiltrate in the 
Gadd45b-/- TME.  Strikingly, the Gadd45b-/- TME also contained an approximately 
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four-fold higher number of TAMs expressing the proinflammatory markers, iNOS and 
COX-2 (14), than the Gadd45b+/+ TME (Figures 5E, Figure S5D).  Reciprocally, 
fibrosarcomas from Gadd45b-/- mice displayed a lower number of Ym-1/Chi3l3+ 
TAMs than tumours from Gadd45b+/+ mice.  Other antiinflammatory activation 
markers were instead unaffected by Gadd45b loss (14).  Hence, TME-associated 
Gadd45b ablation augments TAM infiltration, proinflammatory TAM activation and 
CD8+ T cell-driven antitumor immune responses in fibrosarcoma, thus reinforcing our 
findings with DEN-induced HCC. 
 
TME-Specific Gadd45b Loss Augments Proinflammatory TAM Activation 
and Intratumoural T-Cell Infiltration, While Reducing Ovarian 
Oncogenesis 
To further understand the general significance of Gadd45ȕLQ TAM activation and 
malignant progression, we examined a third cancer model in which IKK/NF-țB was 
shown to drive oncogenesis by operating in myelo-monocytic cells.  We used ID8-
Luc ovarian adenocarcinoma allografts because previous studies had shown that 
macrophage-specific IKKȕ inhibition in this model reverses the typical 
antiinflammatory TAM phenotype and enhances proinflammatory TAM activation, 
thereby causing tumour regression (18).  Consistently, whereas syngeneic ID8-Luc 
tumours grew rapidly in the peritoneum of Gadd45b+/+ mice, tumour growth was 
markedly reduced in Gadd45b-/- mice (Figures 5F-5G), thus demonstrating that TME-
specific Gadd45b ablation also curbs ovarian oncogenesis. 
Notably, intratumoural leukocyte infiltrates yielded a higher number of TAMs, 
T cells and granulocytes, but not B cells, in Gadd45b-/- compared to Gadd45b+/+ mice 
(Figure 5H).  Significantly, as seen in DEN-induced HCC (Figures 2I-2J), the relative 
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T-cell abundance in the Gadd45b-/- TME was largely due to an increased influx of 
CD8+ cytotoxic T cells, which drive effective antitumour immune reactions (3,5) 
(Figure 5H), rather than CD4+ T cells.  Consistent with the increased 
immunoreactivity of the Gadd45b-/- TME, a larger proportion of Gadd45b-/- than 
Gadd45b+/+ TAMs expressed high surface levels of MHC-II (Figures 5I-5J, Figure 
S5E).  Purified Gadd45b-/- TAMs also expressed higher levels of other 
proinflammatory genes, including Nos2, Cxcl9, Cxcl10, Tnfa and Il-6, than 
Gadd45b+/+ TAMs, whereas antiinflammatory activation genes, with the exception of 
Ym-1/Chi3l3, were unaffected by Gadd45b loss (14) (Figure 5K, Figure S5F).  In 
keeping with their heightened state of immune activation, Gadd45b-/- TAMs 
additionally expressed higher levels of immune checkpoint molecule-encoding 
genes, e.g., Ido, Ctla-4, Pd-l1, and B7-h3 (3,4) (Figure 5L), thus confirming the 
observations made with DEN-induced HCC (Figures 3E-3F).  Hence, in three distinct 
models of solid cancer, TME-specific Gadd45b ablation increased proinflammatory 
TAM activation, and intratumoural macrophage and CD8+ T-cell infiltration (see also 
Figures 2G-2J, Figures 3A-3F, Figure 5B, Figure 5E, Figures 5H-5L, Figure S2E, 
Figure S5A, Figures S5D-S5E), resulting in diminished tumour growth.  Interestingly, 
these effects of Gadd45b loss on oncogenesis phenocopied the effects of myeloid-
specific ,..ȕ1)-țB inhibition (16,18,19).  Collectively, these findings underpin the 
importance of the TME-specific role of Gadd45ȕLQcurbing tumour-associated 
inflammation and immune infiltration across different cancer types. 
 
Gadd45b Loss Promotes Proinflammatory Macrophage Activation via a 
Cell-Autonomous Mechanism 
We sought to investigate whether Gadd45ȕPHGLDWHGLWVHIIHFWVRQ TAM activation 
via a cell-autonomous mechanism.  We used an ex-vivo co-culture model system 
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mimicking the tumour-cell/macrophage interactions occuring in cancer, in vivo (18).  
Consistent with our in-vivo findings (Figures 5E, Figure S5D), upon co-culture with 
MCA-203 cells, Gadd45b-/- BM-derived macrophages (BMDMs) expressed markedly 
higher levels of proinflammatory M1-like genes, including Nos2, Tnfa and Cxcl10, 
and lower levels of Arg-1, but not of other antiinflammatory M2-like genes, than 
Gadd45b+/+ BMDMs (Figure 6A).  Similar results were obtained when Gadd45b-/- and 
Gadd45b+/+ BMDMs were co-cultured under similar conditions with ID8-Luc 
carcinoma cells (Figure S6A; see also Figures 5I-5K, Figure S5F).  Hence, *DGGȕ 
plays an essential and cell-autonomous role in restraining proinflammatory 
macrophage activation in response to cues from tumour cells. 
7RFODULI\WKHPHFKDQLVPVE\ZKLFK*DGGȕ governs tumour cell-induced 
macrophage activation, we used a tumour cell-free model system, which employs 
cytokines and TLR ligands to polarise macrophages (7,8).  As expected, 
proinflammatory M1-like genes, as well as known NF-ț%WDUJHWJHQHVLQFOXGLQJ 
Gadd45b, Nfkbia and Tnfaip3, were strongly upregulated by IFN-Ȗ and 
lipopolysaccharide (LPS) in Gadd45b+/+ BMDMs (Figure 6B).  Each of the 
proinflammatory M1-like genes tested, however, was further significantly upregulated 
in IFN-Ȗ/LPS-treated Gadd45b-/- BMDMs compared to Gadd45b+/+ BMDMs.  Immune 
checkpoint molecule-coding genes, including Ido and Pd-l2, were also markedly 
increased in IFN-Ȗ/LPS-stimulated Gadd45b-/- BMDMs relative to controls (Figure 
6B), in keeping with our in vivo findings (Figures 3E-3F, Figure 5L).  By contrast, 
Gadd45b expression was unaffected by treatment with IL-4 and IL-13, as was the 
upregulation of each of the antiinflammatory M2-like genes analysed (Figure 6C).  
We concluded that *DGGȕ is required to curb inflammation and M1-like 
macrophage activation, but is not directly involved in antiinflammatory M2-like 
polarisation, suggesting that the perturbation of the antiinflammatory activation profile 
of Gadd45b-/- TAMs, occasionally observed in co-culture systems and in vivo, 
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stemmed from the skewing of these cells toward a proinflammatory activation 
phenotype.  Collectively, these findings provide a mechanism for the effect of 
Gadd45b loss on tumour-associated inflammation and proinflammatory TAM 
polarisation, in vivo. 
 
Gadd45b Loss Exacerbates Proinflammatory M1-Like Polarisation by 
Enhancing p38 Signalling 
To further the mechanistic understanding of the role of *DGGȕLQ macrophage 
polarisation, we examined STAT1 and MAPK signalling, which upregulates the M1-
like activation programme downstream of IFN-Ȗ receptor (IFN-ȖR) and TLRs (41).  As 
shown in Figures 6D-6E, stimulation with IFN-Ȗ and LPS activated these pathways, 
as well as *DGGȕH[SUHVVLRQ, in Gadd45b+/+ BMDMs.  Yet, Gadd45b deletion had 
no effect on either STAT1 or ERK phosphorylation, nor did it have any effect on JNK 
signalling, nor on NF-ț%DFWLYDWLRQ (Figures 6D-6E).  Surprisingly, Gadd45b loss 
instead markedly augmented and prolonged IFN-Ȗ/LPS-induced p38 signalling, at 
each of the time points examined (Figure 6D).  We concluded that *DGGȕ is 
required to restrict both the magnitude and duration of p38 activation during 
proinflammatory macrophage polarisation. 
Since p38 governs inflammation and expression of many of the 
proinflammatory M1-denoting genes deregulated by Gadd45b loss (42), we 
K\SRWKHVLVHGWKDW*DGGȕ inhibits proinflammatory macrophage polarisation by 
restraining exacerbated p38 signalling.  We therefore investigated whether 
attenuating this signalling reversed the effects of Gadd45b loss on macrophage 
activation.  Notably, treatment with the specific p38ĮȕLQKLELWRU9[
(http://www.kinase-screen.mrc.ac.uk/screening-compounds/348786), downregulated 
the IFN-Ȗ/LPS-dependent induction of each of the proinflammatory M1-like genes 
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that were over-activated by Gadd45b loss to levels similar to those observed in IFN-
Ȗ/LPS-stimulated Gadd45b+/+ BMDMs (Figure 6F; see also Figure 6B).  Comparable 
results were obtained using two additional, structurally unrelated p38 inhibitors, i.e., 
skepinone-L and SB203580, thus excluding any off-target effect of Vx745 (Figures 
S6B-S6C):HFRQFOXGHGWKDW*DGGȕ suppresses proinflammatory macrophage 
activation by selectively downregulating IFN-Ȗ/LPS-induced p38 signalling. 
 
Macrophage-Specific Gadd45b Loss Is Sufficient to Diminish 
Oncogenesis 
To clarify the cause-effect relationship between macrophage-specific Gadd45b 
deficiency and oncogenesis suppression, we generated mice carrying homozygous 
loxP-flanked Gadd45b alleles (Gadd45bF/F mice; Figure 7A, Figures S7A-S7B), and 
crossed them with LysM-cre transgenic mice to obtain myeloid-specific Gadd45b null 
mice (Gadd45bǻ0ǻ0), after Cre-mediated recombination (33) (Figure S7C).  PCR 
analyses confirmed the selective excision of the Gadd45bF alleles and the resulting 
ablation of Gadd45b mRNA expression in Gadd45bǻ0ǻ0 splenic macrophages, but 
not splenic B or T lymphocytes (Figures 7B-7C). 
Given that the LysM-cre transgene, which efficiently deletes loxP-targeted 
alleles in circulating myelo-monocytic cells, is not useful in Kupffer cells (33), 
Gadd45bǻ0ǻ0 mice could not be tested in the DEN HCC model.  We therefore used 
them in the context of MCA-203 fibrosarcoma allografts.  As expected, MCA-203 
tumour growth was unaffected by the presence of Gadd45bF/F alleles (Figures 7D-7E; 
see also Figure 5A).  Strikingly, however, this growth was markedly diminished in 
Gadd45bǻ0ǻ0 mice to a similar extent as seen in Gadd45b-/- mice (Figures 7D-7E; 
see Figure 5A), indicating that macrophage-specific Gadd45b loss is sufficient on its 
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own to fully recapitulate the effect of complete TME-based Gadd45b deficiency on 
inflammation-driven oncogenesis. 
We sought to confirm this macrophage-VSHFLILFUROHRI*DGGȕLQ
oncogenesis by using an alternative mouse model.  To this end, ID8-Luc ovarian 
tumours were allowed to grow in Gadd45b+/+ mice until they became detectable by 
bioimaging, at which point, mice were adoptively transferred with ex-vivo cultured 
Gadd45b+/+ or Gadd45b-/- BMDMs (0 weeks; Figures 7F-7H).  As expected, following 
Gadd45b+/+ BMDM transfer, ovarian tumours continued to grow rapidly (Figures 7G-
7H).  By contrast, the transfer of Gadd45b-/- BMDMs resulted in a significant inhibition 
of tumour growth.  As seen with fibrosarcoma (Figures 7D-7E), the effects of 
macrophage-specific Gadd45b loss on ovarian carcinogenesis recapitulated the 
tumour suppressive effect of complete TME-based Gadd45b ablation (Figures 5F-
5G).  Together with our findings with Gadd45bǻ0ǻ0 mice, these results demonstrate 
that Gadd45ȕRUFKHVWUDWHVWKHWXPRXU-promoting activity of the TME across multiple 
cancer types by operating in myeloid cells.  Collectively, our findings provide a 
mechanism for the immunosuppressive activity of the TME that restricts tumour-
based inflammation and CD8+ T-cell trafficking into tumours and underscore the 
general significance of the NF-ț%-dependent mechanisms mediated by GADD45ȕ in 
human malignant disease. 
 
DISCUSSION 
We have identified an essential innate immunity ³FKHFNSRLQW´ governed by the 
GADD45ȕ-dependent axis of the NF-țB pathway that counters TME-based 
inflammation and CD8+ T-cell trafficking into tumours, the major barrier to effective 
anticancer immunotherapy (3,5).  In three distinct models of cancers that are largely 
refractory to immunotherapies (43-45), myeloid-associated Gadd45b ablation 
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restored proinflammatory TAM activation and intratumoural CD8+ T-cell infiltration, 
leading to diminished tumour growth.  These findings uncover a mechanism for the 
immunusuppressive activity of the TME that fosters oncogenesis.  They also provide 
a basis for the antiinflammatory role that IKKȕNF-țB plays in the myeloid lineage 
and identify a candidate therapeutic route LQWKHLQQDWHLPPXQHV\VWHPIRU³re-
HGXFDWLQJ´TAMs to overcome TME-mediated immunosuppression and, potentially, 
resistance to immunotherapies. 
The treatment of certain malignancies is being revolutionised by the 
development of effective immunotherapies, such as antagonists of immune 
checkpoint molecules (4).  Yet, the large majority of patients fails to respond to these 
treatments, due to the presence of additional immunoinhibitory mechanisms in the 
TME that prevent T-cell access into tumours or cause T-cell exhaustion (3,5).  
However, the limited understanding of these mechanisms, currently precludes the 
development of effective treatment strategies for breaking the TME-mediated 
resistance to immunotherapies.  An attractive approach to overcome this resistance 
would be to harness the innate immune system to induce tumour-based inflammation 
and CD8+ T-cell entry and expansion in the TME.  Together, the myeloid-specific role 
of ,..ȕNF-ț% in suppressing proinflammatory TAM activation (15) and the central 
role of myeloid cells in cancer immune evasion (6,7) provide a compelling rationale 
for therapeutically targeting ,..ȕNF-ț%signalling to reprogramme TAMs toward a 
proinflammatory activation phenotype capable of eliciting local antitumour immune 
responses (18,19).  Yet, no specific IKKȕNF-țB inhibitor has so far been clinically 
approved. 
Our finding that GADD45ȕPHGLDWHVan essential innate immunoinhibitory 
mechanism therefore provides an attractive route downstream in the ,..ȕNF-ț%
pathway to redirect CD8+ T-cell trafficking into tumours and reactivate silenced CD8+ 
T-cell-driven antitumour immune responses.  Congruently, in various cancer types, 
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selective Gadd45ȕDEODWLRQLQP\HOR-monocytic cells closely phenocopied the effects 
RI,..ȕNF-ț%LQDFWLYDWLRQ on oncogenesis (15,16,18,19).  Importantly, myeloid-
specific Gadd45ȕGHOHWLRQDSSHDUHG to override TME-mediated CD8+ T-cell 
exclusion, plausibly through a mechanism involving the upregulation of CXCR3-
binding chemokines, e.g., CXCL9, CXCL10 and CXCL11, which recruit Th-1-type 
and CD8+ effector T cells into tumours and extranodal sites of inflammation (5,46).  
Underscoring the importance of the GADD45ȕ-mediated function, the depletion of 
CD8+ T cells completed abrogated any effect of myelod-restricted Gadd45b loss on 
oncogenesis.  Indeed, Gadd45ȕEORFNDGHDSSHDUHGWRDOVRenhance the ability of the 
TME to support T-cell effector functions by upregulating multiple inflammatory 
mediators, proinflammatory TAM functionalities and MHC-II molecules.  
Underscoring the coordinated nature of its multiple effects on the immune system, 
Gadd45ȕDEODWLRQIXUWKHULPSDUWHGanatomical organisation to adaptive immune 
reactions, enabling them to assemble into well-configured TLSs within endogenously 
arisen tumours. 
Although Pikarsky and colleagues recently suggested that TLSs facilitate 
HCC initiation and early promotion, their study investigated TLS formation in the 
context of the preneoplastic hepatic parenchyma and inflamed neoplastic liver 
outside HCCs (47).  Indeed, T- and B-cell immunity has been previously shown to 
counter DEN-induced HCC development in mouse models (47,48), and intratumoural 
TLSs have been shown to portend a favourable clinical outcome in the majority of 
human cancers, including HCC (37,49).  Future studies will determine the precise 
mechanisms by which GADD45ȕ curbs TME-based TLS formation and cytotoxic 
CD8+ T-cell trafficking and activation, as well as how these mechanisms relate to the 
GADD45ȕ-mediated antiinflammatory function in myeloid cells.  Irrespective of the 
mechanisms, the profound effects of Gadd45b loss on macrophage and T-cell 
accumulation in the TME and intratumoural TLS formation underscore the broad 
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clinical potential of the GADD45ȕ-dependent antiinflammatory axis of the IKK/NF-țB 
pathway in anticancer immunotherapy. 
Since GADD45ȕ also serves as an essential NF-țB-regulated inhibitor of 
cancer cell apoptosis (24), our finding of its unexpected function in the innate 
immune system demonstrates that a single pivotal axis of the IKK/NF-țB pathway, 
i.e., the GADD45ȕ-dependent axis, integrates the oncogenic mechanism 
suppressing tumour-cell apoptosis with the mechanism restraining TME-based 
inflammation and T-cell infiltration.  Hence, GADD45ȕVHUYHV as a central 
downstream hub in the IKK/NF-țB pathway linking cancer and inflammation.  
Surprisingly, GADD45ȕ appears to perform these oncogenic functions via separable, 
tissue-specific mechanisms, attenuating proinflammatory p38 signalling within TAMs 
to restrain proinflammatory activation, while inhibiting apoptosis of cancer cells by 
suppressing JNK/MKK7 signalling (24) (Figure 7I).  Future studies will clarify the 
precise mechanism(s) by which GADD45ȕFXUEVSactivation in myeloid cells and 
confirm the role of this mechanism in oncogenesis.  Irrespective of these 
mechanism(s), our results postulate that targeting the ,..ȕ1)-țB pathway through 
GADD45ȕ inhibition provides a candidate therapeutic route to counter oncogenesis 
by reversing TME-mediated immunosuppression and, at the same time, inducing 
apoptosis of cancer cells, thereby affording dual clinical benefit.  Indeed, a 
combination of oncogenic mechanisms mediated by GADD45ȕ in malignant and 
TME-based myeloid cells likely underpins the correlations between elevated 
GADD45B expression and poor clinical outcome observed in the large majority of 
human cancers. 
To circumvent the limitations of IKK/NF-țB-targeting agents, we recently 
adopted the strategy of therapeutically targeting a non-redundant, pathogenically 
critical axis of the NF-țB pathway ± similarly mediated by GADD45ȕ ± in multiple 
myeloma, rather than NF-țB globally (24,50).  Initial results from the first-in-human 
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FOLQLFDOVWXG\RI*$''ȕ/MKK7-targeting therapeutics in patients with multiple 
myeloma preliminarily indicate the clinical safety of these agents, alongside cancer-
selective pharmacodynamic response (L.T. and G.F., unpublished observations).  
These encouraging early clinical results suggest that it may be possible to similarly 
WDUJHWWKH*$''ȕ-binding factor regulating p38 signalling in myeloid cells, in order 
to elicit antitumour inflammation.  Notably, by converting tumours lacking a 
spontaneous CD8+ T-cell infiltrate into CD8+ T-cell-infiltrated tumours and, 
concurrently, upregulating immune checkpoint molecules, e.g., IDO and PD-1 
OLJDQGVLQQDWHLPPXQRWKHUDSLHVWDUJHWLQJ*$''ȕFRXOGFRQFHLYDEO\RYHUFRPH
primary resistance to adaptive immunotherapies, and thereby increase response 
rates in currently recalcitrant cancer patient subsets (3,5). 
)XUWKHUVWXGLHVZLOOFODULI\WKHFOLQLFDOEHQHILWRIFRPELQLQJ*$''ȕ
inhibitors with conventional immunotherapies.  Notwithstanding, the remarkable 
consistency of the effects of meyloid-specific Gadd45b deletion on oncogenesis and 
the widespread correlation of GADD45B expression with aggressive disease 
pathology across most human cancer types underscore the general clinical 
significance of the GADD45ȕ-mediated mechanism and, consequently, the potential 
of GADD45ȕ-targeting therapeutics in human malignant disease.  The new added 
focus provided by our current findings of a role of GADD45ȕ in innate immune 
regulation will also invigorate the drug discovery effort to develop novel *$''ȕ-
targeting immunotherapeutics for safely and effectively treating oncological diseases. 
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FIGURE LEGENDS 
 
Figure 1. The Widespread Correlation between Elevated GADD45B Expression 
and Poor Clinical Outcome across Human Cancer Types 
(A-M) Relapse-free survival (RFS) and overall survival (OS) in patients with the 
indicated malignant pathologies, representing thirteen out of the top fifteen solid 
cancers for mortality worldwide and deposited in the following publicly available 
datasets: The Cancer Genome Atlas (TCGA) program (A, B, C, F, G, H, K, L and M); 
the French National Cartes d'Identité des Tumeurs (CIT) program (D); the Tumour 
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Banks in the UK and Canada (E); the Chungbuk National University Hospital (I); and 
the Australian Ovarian Cancer Study, Royal Brisbane Hospital, Westmead Hospital 
and Netherlands Cancer Institute (J).  Patients in each series were stratified at 
diagnosis in two groups on the basis of the GADD45B mRNA expression in the 
tumour tissues, as shown.  p values are indicated. 
 
Figure 2. Reduced DEN-Induced HCC Development with Increased 
Intratumoural Immunoinflammatory Infiltrates and TLS Formation in Gadd45b-/- 
Mice 
(A-&1XPEHURIWXPRXUVPP$, tumour surface area (B), and maximum 
tumour diameter (C) in livers of Gadd45b+/+ (n=9) and Gadd45b-/- (n=12) C57BL/6J 
males 9 months after DEN injection (20 mg/kg).  Values denote means ± SEM. 
(D) Gross liver morphology in representative mice from (A-C).  Arrowheads indicate 
tumours. 
(E) Images of H&E staining showing the liver histology in representative mice from 
(A-C).  Hatched lines (top) indicate tumour areas.  Solid lines (top) denote the areas 
magnified in the bottom panels.  The arrowhead (bottom, right) indicates a typical 
immunoinflammatory aggregate.  Scales and magnifications are shown. 
(F) Number of histologically confirmed HCCs per examined liver sections from 
individual mice in (A-C).  Each symbol represents an individual mouse.  Horizontal 
lines denote means. 
(G and H) Percentages of HCCs (G) and combined HCCs and preneoplastic foci (H) 
containing TLSs in Gadd45b+/+ (n=19) and Gadd45b-/- (n=26) 129/SvJxC57BL/6J 
males 11 months after DEN injection (5 mg/kg).  Each symbol represents an 
individual mouse.  Horizontal lines denote means. 
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(I) Immunohistochemical (IHC) analysis showing the percentage of positive area or 
number of positive cells per field at 400x, as stated, of the indicated immune cell 
populations in HCCs from (G).  Values denote means ± SEM (IBA-1: Gadd45b+/+, 
n=47; Gadd45b-/-, n=34.  CD8: Gadd45b+/+, n=37; Gadd45b-/-, n=33.  All other 
markers: Gadd45b+/+, 24Q26; Gadd45b-/-, n=26 or n=27). 
(J) Images of H&E and IHC staining of representative tumour sections from (I).  
Scales and magnifications are shown. 
(A-C and F-I) *, p<0.05; **, p<0.01; ***, p<0.001. 
See also Figure S1 and Figure S2. 
 
Figure 3. Gadd45b Loss Increases Macrophage Infiltration and 
Proinflammatory TAM Activation within HCCs 
(A) IHC analysis showing the percentage of positive area or number of positive cells 
per field at 400x, as stated, for the indicated macrophage (F4/80, IBA-1) and 
proinflammatory and antiinflammatory activation markers in HCCs from Figures 2A-
2C. 
(B) Images of IHC staining of representative tumour sections from (A).  Images of 
Gadd45b-/- HCCs are shown for non-organised immunoinflammatoty cell clusters 
(middle) and well-organised TLSs (right).  Insets denote magnified areas at the top 
right corners. 
(C) Immunofluorescence analysis showing the percentages of IBA-1+ macrophages 
expressing MHC-II per field at 400x in HCCs from Figures 2A-2C. 
(D) Images of immunofluorescence staining of representative tumour sections from 
(C).  Red, anti-IBA-1; green, anti-MHC-II; blue, DAPI. 
(E) IHC analysis showing the percentage of IDO-positive area per field at 400x in 
Gadd45b+/+ and Gadd45b-/- HCCs from (A). 
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(F) Images of IHC staining of representative tumour sections from (E). 
(A, C and E) Values denote means ± SEM (Gadd45b+/+, 14Q30; Gadd45b-/-, 
12Q15).  *, p<0.05; **, p<0.01; ***, p<0.001. 
(B, D and F) Scales and magnifications are shown. 
See also Figure S2 and Figure S3. 
 
Figure 4. Reduction of DEN-Induced HCC Development by Gadd45b Deletion in 
BM-Derived Cells 
(A) Summary of the treatment schedule used for Protocol A. 
%1XPEHUVRIWXPRXUVPPLQOLYHUVRI:7BM:WTHost (n=40), KOBM:KOHost 
(n=25), KOBM:WTHost (n=36) and WTBM:KOHost (n=35) BM chimaeras at the time 
shown in (A). 
(C) Gross liver morphology in representative mice from (B). 
(D) Summary of the treatment schedule used for Protocol B. 
(1XPEHUVRIWXPRXUVPPLQOLYHUVRI:7BM:WTHost (n=24), KOBM:KOHost 
(n=23), KOBM:WTHost (n=24) and WTBM:KOHost (n=29) BM chimaeras at the time 
shown in (D). 
(F) Gross liver morphology in representative mice from (E). 
(A-F) WT, Gadd45b+/+; KO, Gadd45b-/-.  BM chimaeras DUHLGHQWLILHGDVSHU³bone 
marrow GRQRUUHFLSLHQW´JHQRW\SHV 
(B and E) Values denote means ± SEM.  *, p<0.05; **, p<0.01; ***, p<0.001; ****, 
p<0.0001. 
(C and F) Arrowheads denote tumours. 
See also Figure S4. 
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Figure 5. Increased Intratumoural Immunoinflammatory Infiltration, 
Proinflammatory TAM Activation and Reduced Fibrosarcoma and Ovarian 
Carcinoma Growth in Gadd45b-/- mice 
(A) Volumes of subcutaneous MCA-203 fibrosarcoma allografts in Gadd45b+/+ (n=10) 
and Gadd45b-/- (n=9) mice at the times shown. 
(B) IHC analysis showing the percentage of positive areas per field at 400x of the 
indicated immune cell populations in MCA-203 tumours from Gadd45b+/+ (n=7) and 
Gadd45b-/- (n=8) mice 19 days after tumour cell injection. 
(C) Volumes of subcutaneous MCA-203 fibrosarcoma allografts in Gadd45b+/+ and 
Gadd45b-/- mice treated with anti-CD8 or isotype control antibody, as shown, at the 
times indicated.  Gadd45b+/+: anti-CD8 (n=9), isotype (n=7); Gadd45b-/: anti-CD8 
(n=9), isotype (n=4). 
(D) Images of representative tumours from (C) at day 20. 
(E) IHC analysis showing the percentage of positive areas per field at 400x of the 
indicated proinflammatory and antiinflammatory activation markers in the tumours 
from (B). 
(F) Relative luminescence units (RLU) of intraperitoneal ID8-Luc ovarian tumour 
allografts in Gadd45b+/+ (n=10) and Gadd45b-/- (n=10) mice at the times shown after 
tumour cell injection. 
(G) Bioluminescence images of representative mice from (F) presented as a 
pseudocolor scale, whereby red and blue denote the highest and lowest photon flux, 
respectively. 
(H) FACS analysis showing the percentage of the indicated intratumoural immune 
cell populations in Gadd45b+/+ (n=12) and Gadd45b-/- (n=13) mice 60 days after ID8-
Luc tumour cell injection. 
(I) FACS analysis showing the percentage of CD11b+ and F4/80+ double positive 
TAMs expressing high MHC-II levels (MHC-IIhigh) in ID8-Luc tumours from (H). 
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(J) FACS analysis showing the median MHC-II fluorescence intensity of CD11b+ and 
F4/80+ double positive TAMs in ID8-Luc tumours from (H). 
(H-J) Boxes span between the highest values of the first and third quartiles; whiskers 
extend to the highest and lowest values within 1.5x of the inter-quartile range.  Lines 
within boxes denote medians. 
(K and L) qRT-PCR showing the relative mRNA levels of the indicated 
proinflammatory activation markers (K) and immune checkpoint molecules (L) in 
CD11b+ TAMs from Gadd45b+/+ (n=22) and Gadd45b-/- (n=10 or n=12) mice 10 
weeks after ID8-Luc cell injection. 
(A-C, E, F, K and L) Values denote means ± SEM. 
(A-C, E, F, and H-L) *, p<0.05; **, p<0.01; ***, p<0.001. 
See also Figure S5. 
 
Figure 6. Gadd45b Loss Increases Proinflammatory Macrophage Activation by 
Enhancing p38 Signalling 
(A) qRT-PCR showing the relative mRNA levels of the indicated proinflammatory and 
antiinflammatory genes in BMDMs from Gadd45b+/+ and Gadd45b-/- mice after a 24-
hr co-culture with MCA-203 cells. 
(B) qRT-PCR showing the relative mRNA levels of the indicated proinflammatory, 
NF-țB-regulated and immune checkpoint molecule-coding genes in BMDMs from 
Gadd45b-/- and Gadd45b+/+ mice after a 4-hr (Nfkbia, Tnfaip3 and Gadd45b) or 12-hr 
(all other genes) VWLPXODWLRQZLWK/36DQG,)1Ȗ. 
(C) qRT-PCR showing the relative mRNA levels of the indicated antiinflammatory 
genes after a 26-hr stimulation with IL-4 and IL-13. 
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(D and E) Western blots showing total and phosphorylated (P) proteins in Gadd45b+/+ 
and Gadd45b-/- %0'0VDIWHUVWLPXODWLRQZLWK/36DQG,)1ȖIRUWKHWLPHVLQGLFDWHG.  
ȕ-actin is shown as loading control. 
(F) qRT-PCR showing the relative mRNA levels of the indicated proinflammatory 
genes in Gadd45b-/- BMDMs left untreated (-RUWUHDWHGZLWK/36DQG,)1ȖIRU
hr in the presence (+) or absence (-RIWKHSLQKLELWRU9[ȝ0 
(A-C and F) Values denote means ± SEM (A, B [top] and F, n=4; B [bottom] and C, 
n=3).  *, p<0.05; **, p<0.01; ***, p<0.001. 
See also Figure S6. 
 
Figure 7. Suppression of Oncogenesis by Macrophage-Specific Gadd45b 
Deletion 
(A) The targeting strategy for generating the loxP-flanked Gadd45b allele 
(Gadd45bF). 
(B) PCR detecting the wild-type (Gadd45b+), Gadd45bF or excised (Gadd45bǻ) 
Gadd45b alleles in the indicated tissues from Gadd45b+/+ (+/+), Gadd45b+/F (+/F), 
Gadd45bF/F (F/F) or Gadd45bF/F;LysM-cre (ǻ0ǻ0) mice. 
(C) qRT-PCR showing the relative Gadd45b mRNA levels in the indicated tissues 
isolated from Gadd45bF/F (F/F) or Gadd45bF/F;LysM-cre (ǻ0ǻ0) mice. 
(D) Volumes of subcutaneous MCA-203 fibrosarcoma allografts in Gadd45bǻ0ǻ0 
(n=9) and Gadd45bF/F (n=8) mice at the times shown. 
(E) Images of representative tumours from (D) at day 21. 
(F) Summary of the cell injection schedule used in (G and H). 
(G) RLUs of intraperitoneal ID8-Luc ovarian tumour allografts in Gadd45b+/+ mice at 
the times indicated after intraperitoneal injection of Gadd45b+/+ (n=9) or Gadd45b-/- 
(n=12) BMDM pools. 
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(H) Bioluminescence images of representative mice from (G) presented as a 
pseudocolor scale as in Figure 5G. 
(I6FKHPDWLFUHSUHVHQWDWLRQRIWKHRQFRJHQLFIXQFWLRQRI*DGGȕLQPDFURSKDJHV 
(C, D, and G) Values denote means ± SEM.  *, p<0.05; **, p<0.01.  
See also Figure S7. 
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